Table 3.

Grade ≥3 AEs stratified by treatment

Grade ≥3 AEs	5-FU/RT n=132	mFOLFOX-6 n=80
Patients with Grade ≥3 AEs	24 (18%)	9 (11%)
Most common Grade ≥3 AEs
Gastrointestinal	10 (8%)	0 (0%)
Abdominal/Rectal pain	6 (5%)	1 (1%)
Vascular	0 (0%)	2 (3%)
Infection	2 (2%)	0 (0%)
Hematologic	3 (2%)	4 (5%)
Constitutional symptoms	3 (2%)	0 (0%)
Cardiac event	0 (0%)	1 (1%)
Other (Allergy/skin/rash)	8 (6%)	3 (4%)

AE: Adverse event; 5-FU: 5-fluorouracil; RT: radiation therapy; mFOLFOX-6: modified FOLFOX-6 chemotherapy.